| __timestamp | Alkermes plc | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 14993000000 |
| Thursday, January 1, 2015 | 311558000 | 14247000000 |
| Friday, January 1, 2016 | 374130000 | 14192000000 |
| Sunday, January 1, 2017 | 421578000 | 14997000000 |
| Monday, January 1, 2018 | 526408000 | 16471000000 |
| Tuesday, January 1, 2019 | 599449000 | 14369000000 |
| Wednesday, January 1, 2020 | 538827000 | 14197000000 |
| Friday, January 1, 2021 | 560977000 | 14886000000 |
| Saturday, January 1, 2022 | 605747000 | 14253000000 |
| Sunday, January 1, 2023 | 689751000 | 12489000000 |
| Monday, January 1, 2024 | 645238000 | 12566000000 |
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Alkermes plc from 2014 to 2023. Over this period, Novartis AG consistently outspent Alkermes plc, with its SG&A expenses peaking in 2018 at approximately $16.5 billion. In contrast, Alkermes plc showed a steady increase, reaching around $690 million in 2023, marking a 245% rise from 2014. This trend highlights Novartis AG's expansive operational scale, while Alkermes plc's growth reflects its strategic investments in market expansion. The data underscores the contrasting financial strategies of these pharmaceutical giants, offering insights into their market positioning and operational priorities.
Breaking Down SG&A Expenses: Johnson & Johnson vs Alkermes plc
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Alkermes plc
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Alkermes plc
Alkermes plc and MorphoSys AG: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Alkermes plc vs Evotec SE Trends and Insights